TW202200603A - 對抗ｓａｒｓ－ｃｏｖ－２之結構蛋白質之抗體之抗原決定區、和該抗原決定區反應之抗體、使用該抗體檢測ｓａｒｓ－ｃｏｖ－２之方法、含有該抗體之ｓａｒｓ－ｃｏｖ－２檢測套組、檢測含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體之方法、含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體檢測套組、含有該抗原決定區之多胜肽之ｓａｒｓ－ｃｏｖ－２用疫苗以及含有該抗體之ｓａｒｓ－ｃｏｖ－２傳染病治療藥 - Google Patents

對抗ｓａｒｓ－ｃｏｖ－２之結構蛋白質之抗體之抗原決定區、和該抗原決定區反應之抗體、使用該抗體檢測ｓａｒｓ－ｃｏｖ－２之方法、含有該抗體之ｓａｒｓ－ｃｏｖ－２檢測套組、檢測含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體之方法、含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體檢測套組、含有該抗原決定區之多胜肽之ｓａｒｓ－ｃｏｖ－２用疫苗以及含有該抗體之ｓａｒｓ－ｃｏｖ－２傳染病治療藥 Download PDF

Info

Publication number
TW202200603A
TW202200603A TW110108040A TW110108040A TW202200603A TW 202200603 A TW202200603 A TW 202200603A TW 110108040 A TW110108040 A TW 110108040A TW 110108040 A TW110108040 A TW 110108040A TW 202200603 A TW202200603 A TW 202200603A
Authority
TW
Taiwan
Prior art keywords
cov
sars
protein
seq
antibody
Prior art date
Application number
TW110108040A
Other languages
English (en)
Chinese (zh)
Inventor
小笠原真也
Original Assignee
日商電化股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商電化股份有限公司 filed Critical 日商電化股份有限公司
Publication of TW202200603A publication Critical patent/TW202200603A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110108040A 2020-03-10 2021-03-08 對抗ｓａｒｓ－ｃｏｖ－２之結構蛋白質之抗體之抗原決定區、和該抗原決定區反應之抗體、使用該抗體檢測ｓａｒｓ－ｃｏｖ－２之方法、含有該抗體之ｓａｒｓ－ｃｏｖ－２檢測套組、檢測含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體之方法、含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體檢測套組、含有該抗原決定區之多胜肽之ｓａｒｓ－ｃｏｖ－２用疫苗以及含有該抗體之ｓａｒｓ－ｃｏｖ－２傳染病治療藥 TW202200603A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020040960 2020-03-10
JP2020-040960 2020-03-10

Publications (1)

Publication Number Publication Date
TW202200603A true TW202200603A (zh) 2022-01-01

Family

ID=77670521

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110108040A TW202200603A (zh) 2020-03-10 2021-03-08 對抗ｓａｒｓ－ｃｏｖ－２之結構蛋白質之抗體之抗原決定區、和該抗原決定區反應之抗體、使用該抗體檢測ｓａｒｓ－ｃｏｖ－２之方法、含有該抗體之ｓａｒｓ－ｃｏｖ－２檢測套組、檢測含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體之方法、含有該抗原決定區之多胜肽之抗ｓａｒｓ－ｃｏｖ－２抗體檢測套組、含有該抗原決定區之多胜肽之ｓａｒｓ－ｃｏｖ－２用疫苗以及含有該抗體之ｓａｒｓ－ｃｏｖ－２傳染病治療藥

Country Status (6)

Country Link
US (1) US20230348570A1 (https=)
EP (1) EP4119575A4 (https=)
JP (2) JPWO2021181994A1 (https=)
CN (1) CN115867573A (https=)
TW (1) TW202200603A (https=)
WO (1) WO2021181994A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
JP2022130332A (ja) * 2021-02-25 2022-09-06 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体
JP7728100B2 (ja) * 2021-05-11 2025-08-22 富士レビオ株式会社 ＳＡＲＳ－ＣｏＶ－２の免疫学的検出方法および試薬
JP7216948B1 (ja) * 2021-06-16 2023-02-02 積水メディカル株式会社 ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片
JP7105970B1 (ja) * 2021-06-16 2022-07-25 積水メディカル株式会社 ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット
WO2023068282A1 (ja) * 2021-10-21 2023-04-27 美幸 徳田 飲食品、食品添加物、サプリメント、化粧品、抗体、医薬、およびその製造方法
WO2023068343A1 (ja) * 2021-10-21 2023-04-27 美幸 徳田 飲食品、食品添加物、サプリメント、化粧品、抗体、医薬、およびその製造方法
CN113943349A (zh) * 2021-10-22 2022-01-18 华瑞同康生物技术（深圳）有限公司 靶向识别抗新冠病毒中和抗体N-IgY-pAbs的核心氨基酸序列组及应用
KR20230095025A (ko) * 2021-12-20 2023-06-28 아이진 주식회사 변이 SARS-CoV-2 백신 조성물 및 이의 용도
JP2023128698A (ja) * 2022-03-04 2023-09-14 公立大学法人横浜市立大学 変異株を含む、体液中のＳＡＲＳ－ＣｏＶ－２抗原に対する抗ＳＡＲＳ－ＣｏＶ－２抗体、該抗体を用いてＳＡＲＳ－ＣｏＶ－２を検出する方法、および該抗体を含むキット
CN114560929B (zh) * 2022-03-21 2023-07-04 深圳国家感染性疾病临床医学研究中心 针对冠状病毒np蛋白的单克隆抗体及其应用
CN114790239B (zh) * 2022-03-29 2023-03-21 苏州东抗生物科技有限公司 一种抗冠状病毒n蛋白的抗体及其应用
TW202434887A (zh) 2023-02-08 2024-09-01 日商電化股份有限公司 SARS-CoV-2之檢測方法及用於其之套組
WO2024166922A1 (ja) 2023-02-08 2024-08-15 デンカ株式会社 ＳＡＲＳ－ＣｏＶ－２の検出方法及びそのためのキット
WO2024166920A1 (ja) 2023-02-08 2024-08-15 デンカ株式会社 抗ｓａｒｓ－ｃｏｖ－２モノクローナル抗体並びにそれを用いたｓａｒｓ－ｃｏｖ－２の免疫測定方法及び免疫測定器具
KR20250140089A (ko) 2023-02-08 2025-09-24 덴카 주식회사 SARS-CoV-2의 검출 방법 및 이를 위한 키트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441677A1 (en) * 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus
US20080254440A1 (en) * 2003-10-31 2008-10-16 Yoshiaki Uchida Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and Immunoassay Reagent Using the Antibody
CA2549188A1 (fr) * 2003-12-02 2005-06-23 Universite Paris 7 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras
US20090280507A1 (en) * 2005-10-11 2009-11-12 Sysmex Corporation Method for measurement of sars virus nucleocapsid protein, reagent kit for the measurement, test device, monoclonal antibody directed against sars virus nucleocapsid protein, and hybridoma capable of producing the monoclonal antibody
US12029786B2 (en) * 2020-02-07 2024-07-09 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.

Also Published As

Publication number Publication date
JP2024150516A (ja) 2024-10-23
EP4119575A1 (en) 2023-01-18
JP7801399B2 (ja) 2026-01-16
EP4119575A4 (en) 2024-07-03
US20230348570A1 (en) 2023-11-02
JPWO2021181994A1 (https=) 2021-09-16
CN115867573A (zh) 2023-03-28
WO2021181994A1 (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7801399B2 (ja) ＳＡＲＳ－ＣｏＶ－２の構造タンパク質に対する抗体のエピトープ、該エピトープに反応する抗体、該抗体を用いてＳＡＲＳ－ＣｏＶ－２を検出する方法、該抗体を含むＳＡＲＳ－ＣｏＶ－２検出キット、該エピトープのポリペプチドを含む抗ＳＡＲＳ－ＣｏＶ－２抗体を検出する方法、該エピトープのポリペプチドを含む抗ＳＡＲＳ－ＣｏＶ－２抗体検出キット、該エピトープのポリペプチドを含むＳＡＲＳ－ＣｏＶ－２用ワクチン及び該抗体を含むＳＡＲＳ－ＣｏＶ－２感染症治療薬
WO2022077613A1 (zh) 一种新型冠状病毒 s 蛋白的 b 细胞线性抗原表位、抗体、鉴定方法及应用
CN107430124B (zh) 肺炎支原体的免疫学检测法和试剂盒
JP2018173418A (ja) マイコプラズマ・ニューモニエの免疫学的検出法およびキット
KR20240022452A (ko) SARS-CoV-2의 면역 측정 방법 및 면역 측정 키트
US20230235028A1 (en) Antibody against sars-cov-2, method for detecting sars-cov-2 using antibody and kit containing antibody
JP7216948B1 (ja) ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片
JP6616333B2 (ja) マイコプラズマ・ニューモニエの免疫学的検出法およびキット
CN112745387B (zh) 抗猪塞尼卡谷病毒单克隆抗体及其应用
EP4116324B1 (en) Adenovirus immunoassay method and adenovirus immunoassay instrument
EP4116323A1 (en) Adenovirus immunoassay method and immunoassay instrument
EP4116321A1 (en) Adenovirus immunization measurement method and immunization measurement device
CN115850454B (zh) 抗柯萨奇病毒a16型的抗体及其制备方法和应用
EP4116322A1 (en) Adenovirus immunoassay method and immunoassay instrument
GAO et al. A novel multi-epitope recombinant protein for diagnosis of African swine fever
CN119320447A (zh) 一种小反刍兽疫病毒特异性单克隆抗体及其应用